200 related articles for article (PubMed ID: 24990206)
1. Anti-HIV small-molecule binding in the peptide subpocket of the CXCR4:CVX15 crystal structure.
Cox BD; Prosser AR; Katzman BM; Alcaraz AA; Liotta DC; Wilson LJ; Snyder JP
Chembiochem; 2014 Jul; 15(11):1614-20. PubMed ID: 24990206
[TBL] [Abstract][Full Text] [Related]
2. Hologram quantitative structure activity relationship, docking, and molecular dynamics studies of inhibitors for CXCR4.
Zhang C; Du C; Feng Z; Zhu J; Li Y
Chem Biol Drug Des; 2015 Feb; 85(2):119-36. PubMed ID: 24923360
[TBL] [Abstract][Full Text] [Related]
3. Progress toward rationally designed small-molecule peptide and peptidomimetic CXCR4 antagonists.
Våbenø J; Haug BE; Rosenkilde MM
Future Med Chem; 2015; 7(10):1261-83. PubMed ID: 26144264
[TBL] [Abstract][Full Text] [Related]
4. The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor.
Mosi RM; Anastassova V; Cox J; Darkes MC; Idzan SR; Labrecque J; Lau G; Nelson KL; Patel K; Santucci Z; Wong RS; Skerlj RT; Bridger GJ; Huskens D; Schols D; Fricker SP
Biochem Pharmacol; 2012 Feb; 83(4):472-9. PubMed ID: 22146583
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors.
Wong RS; Bodart V; Metz M; Labrecque J; Bridger G; Fricker SP
Mol Pharmacol; 2008 Dec; 74(6):1485-95. PubMed ID: 18768385
[TBL] [Abstract][Full Text] [Related]
6. Insights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors.
Das D; Maeda K; Hayashi Y; Gavande N; Desai DV; Chang SB; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2015 Apr; 59(4):1895-904. PubMed ID: 25583709
[TBL] [Abstract][Full Text] [Related]
7. Tetrahydroisoquinoline CXCR4 Antagonists Adopt a Hybrid Binding Mode within the Peptide Subpocket of the CXCR4 Receptor.
Katzman BM; Cox BD; Prosser AR; Alcaraz AA; Murat B; Héroux M; Tebben A; Zhang Y; Schroeder GM; Snyder JP; Wilson LJ; Liotta DC
ACS Med Chem Lett; 2019 Jan; 10(1):67-73. PubMed ID: 30655949
[TBL] [Abstract][Full Text] [Related]
8. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists.
Wu B; Chien EY; Mol CD; Fenalti G; Liu W; Katritch V; Abagyan R; Brooun A; Wells P; Bi FC; Hamel DJ; Kuhn P; Handel TM; Cherezov V; Stevens RC
Science; 2010 Nov; 330(6007):1066-71. PubMed ID: 20929726
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210.
Johnson VA; Cramer YS; Rosenkranz SL; Becker S; Klingman KL; Kallungal B; Coakley E; Acosta EP; Calandra G; Saag MS;
AIDS Res Hum Retroviruses; 2019 Aug; 35(8):691-697. PubMed ID: 31099252
[TBL] [Abstract][Full Text] [Related]
10. Studying the binding interactions of allosteric agonists and antagonists of the CXCR4 receptor.
Planesas JM; Pérez-Nueno VI; Borrell JI; Teixidó J
J Mol Graph Model; 2015 Jul; 60():1-14. PubMed ID: 26080355
[TBL] [Abstract][Full Text] [Related]
11. Impact of the CXCR4 structure on docking-based virtual screening of HIV entry inhibitors.
Planesas JM; Pérez-Nueno VI; Borrell JI; Teixidó J
J Mol Graph Model; 2012 Sep; 38():123-36. PubMed ID: 23079643
[TBL] [Abstract][Full Text] [Related]
12. Computational analysis of the structural mechanism of inhibition of chemokine receptor CXCR4 by small molecule antagonists.
Kawatkar SP; Yan M; Gevariya H; Lim MY; Eisold S; Zhu X; Huang Z; An J
Exp Biol Med (Maywood); 2011 Jul; 236(7):844-50. PubMed ID: 21697335
[TBL] [Abstract][Full Text] [Related]
13. Chemokine receptor CXCR4 oligomerization is disrupted selectively by the antagonist ligand IT1t.
Ward RJ; Pediani JD; Marsango S; Jolly R; Stoneman MR; Biener G; Handel TM; Raicu V; Milligan G
J Biol Chem; 2021; 296():100139. PubMed ID: 33268380
[TBL] [Abstract][Full Text] [Related]
14. Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions.
Yoshikawa Y; Kobayashi K; Oishi S; Fujii N; Furuya T
Bioorg Med Chem Lett; 2012 Mar; 22(6):2146-50. PubMed ID: 22365757
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.
Skerlj RT; Bridger GJ; Kaller A; McEachern EJ; Crawford JB; Zhou Y; Atsma B; Langille J; Nan S; Veale D; Wilson T; Harwig C; Hatse S; Princen K; De Clercq E; Schols D
J Med Chem; 2010 Apr; 53(8):3376-88. PubMed ID: 20297846
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070.
O'Boyle G; Swidenbank I; Marshall H; Barker CE; Armstrong J; White SA; Fricker SP; Plummer R; Wright M; Lovat PE
Br J Cancer; 2013 Apr; 108(8):1634-40. PubMed ID: 23538388
[TBL] [Abstract][Full Text] [Related]
17. Biological and mutational analyses of CXCR4-antagonist interactions and design of new antagonistic analogs.
Meng Q; Zhu R; Mao Y; Zhu S; Wu Y; Huang LSM; Ciechanover A; An J; Xu Y; Huang Z
Biosci Rep; 2023 Dec; 43(12):. PubMed ID: 38131305
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.
Morimoto M; Matsuo Y; Koide S; Tsuboi K; Shamoto T; Sato T; Saito K; Takahashi H; Takeyama H
BMC Cancer; 2016 May; 16():305. PubMed ID: 27175473
[TBL] [Abstract][Full Text] [Related]
19. Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities.
Zhang H; Kang D; Huang B; Liu N; Zhao F; Zhan P; Liu X
Eur J Med Chem; 2016 May; 114():65-78. PubMed ID: 26974376
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of CXCR4 ligands.
Mona CE; Besserer-Offroy É; Cabana J; Leduc R; Lavigne P; Heveker N; Marsault É; Escher E
Org Biomol Chem; 2016 Nov; 14(43):10298-10311. PubMed ID: 27752700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
